Cargando…
Timing of multikinase inhibitor initiation in differentiated thyroid cancer
There are limited treatment options for patients with radioactive iodine refractory, progressive differentiated thyroid cancer. Although there is consensus that multikinase inhibitor therapy should be considered in patients with progressive disease with considerable tumor load or symptomatic disease...
Autores principales: | Brose, Marcia S, Smit, Johannes, Lin, Chia-Chi, Pitoia, Fabian, Fellous, Marc, DeSanctis, Yoriko, Schlumberger, Martin, Tori, Masayuki, Sugitani, Iwao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446590/ https://www.ncbi.nlm.nih.gov/pubmed/28270435 http://dx.doi.org/10.1530/ERC-17-0016 |
Ejemplares similares
-
Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018) -
Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial
por: Huillard, Olivier, et al.
Publicado: (2019) -
Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019) -
Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014) -
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer
por: Wirth, Lori J, et al.
Publicado: (2022)